Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Emmanuel De La Mora Jimenez"'
Autor:
Luis G. Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo, Jaafar Bennouna, Michael Schenker, Ying Cheng, Oscar Juan-Vidal, Hideaki Mizutani, Alejo Lingua, Felipe Reyes-Cosmelli, Niels Reinmuth, Juliana Menezes, Jacek Jassem, Svetlana Protsenko, Eduardo Richardet, Enriqueta Felip, Kynan Feeney, Bogdan Zurawski, Aurelia Alexandru, Emmanuel de la Mora Jimenez, Shaker Dakhil, Shun Lu, Martin Reck, Thomas John, Nan Hu, Xiaoqing Zhang, Judi Sylvester, Laura J. Eccles, Diederik J. Grootendorst, David Balli, Jaclyn Neely, David P. Carbone
Publikováno v:
Scientia
Non–small cell lung cancer; Brain metastases; Somatic mutations Càncer de pulmó de cèl·lules no petites; Metàstasis cerebrals; Mutacions somàtiques Cáncer de pulmón de células no pequeñas; Metástasis cerebrales; Mutaciones somáticas Int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1273c44ad3440298c0d6bb6ae78e198
https://doi.org/10.1016/j.jtho.2022.10.014
https://doi.org/10.1016/j.jtho.2022.10.014
Autor:
Luis G. Paz-Ares, Tudor-Eliade Ciuleanu, Manuel Cobo-Dols, Jaafar Bennouna, Ying Cheng, Hideaki Mizutani, Alejo Lingua, Felipe Reyes, Niels Reinmuth, Juliana Janoski De Menezes, Jacek Jassem, Svetlana Protsenko, Kynan Feeney, Emmanuel De La Mora Jimenez, Shun Lu, Tom John, David Paul Carbone, Xiaoqing Zhang, Nan Hu, Martin Reck
Publikováno v:
Journal of Clinical Oncology. 40:LBA9026-LBA9026
LBA9026 Background: In CheckMate 9LA (NCT03215706), 1L NIVO + IPI combined with 2 cycles of chemo was shown to provide survival benefit vs chemo alone in pts with metastatic NSCLC. Here, we report updated efficacy and safety with a 3-year minimum fol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0740151d5d852cc50a6bea934cb00193
https://doi.org/10.1200/jco.2022.40.17_suppl.lba9026
https://doi.org/10.1200/jco.2022.40.17_suppl.lba9026
Autor:
Helena Linardou, Xiaowu Sun, Krysztof Lesniewski-Kmak, Michael Schenker, Samreen Ahmed, Kenneth J. O'Byrne, Konstantinos N. Syrigos, Martin Reck, Alejandro Moreno-Koehler, Fiona Taylor, Makoto Nishio, John R. Penrod, Yong Yuan, Clarisse Audigier-Valette, Jong Seok Lee, Tudor Ciuleanu, Emmanuel de la Mora Jimenez, F. E. Nathan, Istvan Albert, B. Zurawski, Pamela Salman, Gregory A. Otterson, Steven I. Blum
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 16(4)
Introduction In CheckMate 227 (NCT02477826), patients with treatment-naive stage IV or recurrent NSCLC and 1% or greater tumor programmed death ligand 1 expression had significantly improved overall survival with nivolumab plus ipilimumab versus chem
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ae0341587342c02a4c9bbdd1dba102b
https://pubmed.ncbi.nlm.nih.gov/33781441
https://pubmed.ncbi.nlm.nih.gov/33781441